9 May 2024
A study from the Hackett group at EMBL Rome led to the development of an epigenetic editing system that allows to precisely program chromatin modifications at any specific position in the genome, to understand their causal role in transcription regulation.
SCIENCE & TECHNOLOGY
6 July 2023
Through the collaborative framework agreement, EMBL and ZEISS aim to accelerate the development of imaging technology to advance life science research.
CONNECTIONSLAB MATTERS
2023
connectionslab-matters
5 July 2023
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS
2023
announcementsembl-announcements
31 May 2023
EMBL researchers and collaborators have begun an impactful innovation-development journey, thanks to a European Commission ‘IMAGINE’ grant.
CONNECTIONSLAB MATTERS
2023
connectionslab-matters
4 May 2023
Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme.
CONNECTIONSLAB MATTERS
2023
connectionslab-matters
16 February 2023
EMBL is one of the partners of this project that aims to accelerate drug discovery and development, bringing in expertise from EMBL Grenoble and EMBL-EBI.
LAB MATTERSSCIENCE & TECHNOLOGY
2023
lab-mattersscience-technology